W

Wagner Macula & Retina Center | Norfolk, VA

Research site

(Unclaimed)

Location

6160 Kempsville Circle, Norfolk, Virginia, United States of America

Site insights

Top conditions

Top treatments

Faricimab

Ranibizumab

Lampalizumab

YD312

THR-149

CBT-001

Eplerenone

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 16 total trials

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle i...

Enrolling

Pterygium

Drug: Vehicle

Drug: CBT-001

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting

Neovascular Age-related Macular Degeneration

Other: Sham Procedure

Drug: Faricimab

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling

Wet Age-related Macular Degeneration

WetAMD

Genetic: RGX-314 Dose 2

Biological: Aflibercept (EYLEA®)